Kanada - Inggris - Health Canada

glaxosmithkline inc - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm-197 protein - powder for suspension - 10mcg; 25mcg - meningococcal group c oligosaccharide 10mcg; corynebacterium diphtheriae crm-197 protein 25mcg - toxoids

Kanada - Inggris - Health Canada

pfizer canada ulc - pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 9v; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19f; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 6b; corynebacterium diphtheriae crm-197 protein - suspension - 2mcg; 2mcg; 2mcg; 2mcg; 2mcg; 2mcg; 4mcg; 20mcg - pneumococcal polysaccharide serotype 4 2mcg; pneumococcal polysaccharide serotype 9v 2mcg; pneumococcal polysaccharide serotype 14 2mcg; pneumococcal polysaccharide serotype 18c 2mcg; pneumococcal polysaccharide serotype 19f 2mcg; pneumococcal polysaccharide serotype 23f 2mcg; pneumococcal polysaccharide serotype 6b 4mcg; corynebacterium diphtheriae crm-197 protein 20mcg - vaccines

Kanada - Inggris - Health Canada

nuron biotech b.v. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm-197 protein - suspension - 10mcg; 15mcg - meningococcal group c oligosaccharide 10mcg; corynebacterium diphtheriae crm-197 protein 15mcg - vaccines

Kanada - Inggris - Health Canada

glaxosmithkline inc - meningococcal group a oligosaccharide; meningococcal group c oligosaccharide; meningococcal group w-135 oligosaccharide; meningococcal group y oligosaccharide; corynebacterium diphtheriae crm-197 protein - solution - 10mcg; 5mcg; 5mcg; 5mcg; 47mcg - meningococcal group a oligosaccharide 10mcg; meningococcal group c oligosaccharide 5mcg; meningococcal group w-135 oligosaccharide 5mcg; meningococcal group y oligosaccharide 5mcg; corynebacterium diphtheriae crm-197 protein 47mcg - vaccines

Kanada - Inggris - Health Canada

glaxosmithkline inc - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm-197 protein - suspension - 10mcg; 25mcg - meningococcal group c oligosaccharide 10mcg; corynebacterium diphtheriae crm-197 protein 25mcg - toxoids

Amerika Serikat - Inggris - NLM (National Library of Medicine)

mcm vaccine co. - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37), - vaxelis™ is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to haemophilus influenzae (h. influenzae ) type b. vaxelis is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday). do not administer vaxelis to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to a previous dose of vaxelis, any ingredient of vaxelis, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis b vaccine, or h. influenzae type b vaccine [see description (11) .] do not administer vaxelis to anyone with a history of encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis-containing vaccine, that is not attributable to another identifiable cause. do not administer vaxelis to anyone with a history of progressive neurologic disorder, includ

Amerika Serikat - Inggris - NLM (National Library of Medicine)

sanofi pasteur inc. - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37 - quadracel® is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis and poliomyelitis. a single dose of quadracel is approved for use as a fifth dose in the diphtheria, tetanus, pertussis (dtap) vaccination series, and as a fourth or fifth dose in the inactivated poliovirus (ipv) vaccination series in children 4 through 6 years of age whose previous dtap vaccine doses have been with pentacel® [diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine], daptacel® (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) and/or vaxelis (diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, haemophilus b conjugate and hepatitis b vaccine). severe allergic reaction (e.g., anaphylaxis) to any ingredient of quadracel [see description (11) ] or following any diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, or inactivated poliovi

Amerika Serikat - Inggris - NLM (National Library of Medicine)

msp vaccine company - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37 - vaxelis® is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to haemophilus influenzae (h. influenzae ) type b. vaxelis is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday). do not administer vaxelis to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to a previous dose of vaxelis, any ingredient of vaxelis, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis b vaccine, or h. influenzae type b vaccine [see description (11) .] do not administer vaxelis to anyone with a history of encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis-containing vaccine, that is not attributable to another identifiable cause. do not administer vaxelis to anyone with a history of progressive neurologic disorder, inclu

Kanada - Inggris - Health Canada

merck canada inc - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 19f; pneumococcal polysaccharide serotype 22f; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 33f; corynebacterium diphtheriae crm-197 protein - suspension - 2mcg; 2mcg; 2mcg; 2mcg; 2mcg; 4mcg; 2mcg; 2mcg; 2mcg; 2mcg; 2mcg; 2mcg; 2mcg; 2mcg; 2mcg; 30mcg - pneumococcal polysaccharide serotype 1 2mcg; pneumococcal polysaccharide serotype 3 2mcg; pneumococcal polysaccharide serotype 4 2mcg; pneumococcal polysaccharide serotype 5 2mcg; pneumococcal polysaccharide serotype 6a 2mcg; pneumococcal polysaccharide serotype 6b 4mcg; pneumococcal polysaccharide serotype 7f 2mcg; pneumococcal polysaccharide serotype 9v 2mcg; pneumococcal polysaccharide serotype 14 2mcg; pneumococcal polysaccharide serotype 18c 2mcg; pneumococcal polysaccharide serotype 19a 2mcg; pneumococcal polysaccharide serotype 19f 2mcg; pneumococcal polysaccharide serotype 22f 2mcg; pneumococcal polysaccharide serotype 23f 2mcg; pneumococcal polysaccharide serotype 33f 2mcg; corynebacterium diphtheriae crm-197 protein 30mcg - vaccines

Kanada - Inggris - Health Canada

pfizer canada ulc - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 8; pneumococcal polysaccharide serotype 9v; pneumococcal polysaccharide serotype 10a; pneumococcal polysaccharide serotype 11a; pneumococcal polysaccharide serotype 12f; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 15b; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 19f; pneumococcal polysaccharide serotype 22f; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 33f; corynebacterium diphtheriae crm-197 protein - suspension - 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 4.4mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 51mcg - pneumococcal polysaccharide serotype 1 2.2mcg; pneumococcal polysaccharide serotype 3 2.2mcg; pneumococcal polysaccharide serotype 4 2.2mcg; pneumococcal polysaccharide serotype 5 2.2mcg; pneumococcal polysaccharide serotype 6a 2.2mcg; pneumococcal polysaccharide serotype 6b 4.4mcg; pneumococcal polysaccharide serotype 7f 2.2mcg; pneumococcal polysaccharide serotype 8 2.2mcg; pneumococcal polysaccharide serotype 9v 2.2mcg; pneumococcal polysaccharide serotype 10a 2.2mcg; pneumococcal polysaccharide serotype 11a 2.2mcg; pneumococcal polysaccharide serotype 12f 2.2mcg; pneumococcal polysaccharide serotype 14 2.2mcg; pneumococcal polysaccharide serotype 15b 2.2mcg; pneumococcal polysaccharide serotype 18c 2.2mcg; pneumococcal polysaccharide serotype 19a 2.2mcg; pneumococcal polysaccharide serotype 19f 2.2mcg; pneumococcal polysaccharide serotype 22f 2.2mcg; pneumococcal polysaccharide serotype 23f 2.2mcg; pneumococcal polysaccharide serotype 33f 2.2mcg; corynebacterium diphtheriae crm-197 protein 51mcg